Month: April 2016

Life Expectancy Rising in HIV Group Over 50, But Still Lags General Population

Estimated median survival in the HIV group rose from 11.8 years in 1996-1999 to 17.8 years in 2000-2005 and to 22.5 years in 2006-2014. Median survival in general population controls was 30.2 years across all three periods. Mortality rate ratio comparing HIV-positive people with controls was highest among 50- to 55-year-olds (3.8) and declined in …

Life Expectancy Rising in HIV Group Over 50, But Still Lags General Population Read More »

New HIV Drug Has Potential for Weekly or Once-Yearly Dosing

One of the surprises at CROI 2016 was the first virological data from a new highly potent NRTI that in a slow-release formulation has the potential for annual dosing and that is undergoing research as both treatment and PrEP. In an oral late-breaker, Jay Grobler from Merck presented results from a dose-ranging study in macaques …

New HIV Drug Has Potential for Weekly or Once-Yearly Dosing Read More »

Switching HIV+ Patients From Stribld to Genvoya Improved Proteinuria but Not eGFR

CROI 2016 Conference Abstract Number:  795 Safety of Tenofovir Alafenamide in Renal Impairment Author(s):  Anton Pozniak2, Jose R Arribas3, Samir K. Gupta4, Frank A. Post5, Anchalee Avihingsanon6, Gordon Crofoot7, Kenneth A. Lichtenstein8, Moti Ramgopal9, Ploenchan Chetchotisakd10, Marshall W. Fordyce11 Clinical Research, Gilead Sciences Inc, Foster City, CA, United States. 2 Chelsea and Westminster Hospital NHS Foundation Trust, London, …

Switching HIV+ Patients From Stribld to Genvoya Improved Proteinuria but Not eGFR Read More »

HIV Mutates Around Promising Gene Editing Technology (CRISPR-CAS 9)

HIV can defeat efforts to cripple it with CRISPR gene-editing technology, researchers say. And the very act of editing — involving snipping at the virus’s genome — may introduce mutations that help it to resist attack. At least half a dozen papers over the past three years have explored using the popular CRISPR–Cas9 gene editing …

HIV Mutates Around Promising Gene Editing Technology (CRISPR-CAS 9) Read More »

Scroll to Top